Background: Eribulin shows some activity in controlling brain metastasis in breast cancer. Methods: This observational, multicenter study evaluated brain disease control rates, survival and safety in patients with brain metastatic breast cancer treated with eribulin in clinical practice. Results: A total of 34 patients were enrolled (mean age 49 years, 91% with visceral metastases) and 29 were evaluable for brain disease. Fourteen achieved disease control and showed a longer time without progression: 10 months (95% CI: 2.3-17.7) versus 4 months (95% CI: 3.3-4.7) in the control group (p = 0.029). Patients with clinical benefits at 6 months had longer survival. Leukopenia and neutropenia were the most frequent grade 3-4 toxicities. Conclusion: Eribulin confirms its effectiveness in patients with brain metastatic breast cancer. Further studies on larger cohorts are needed to confirm the results.
Eribulin in brain metastases of breast cancer. outcomes of the EBRAIM prospective observational trial / Fabi, A; Terrenato, I; Vidiri, A; Villans, V; Tanzilli, A; Airoldi, M; Pedani, F; Magri, V; Palleschi, M; Donadio, M; Catania, G; Nistico, C; Carapella, C; Ruda, R; Pace, A; Maschio, M; Telera, S; Cognetti, F. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - May 28(2021), pp. 1-12. [10.2217/fon-2021-0300]
Eribulin in brain metastases of breast cancer. outcomes of the EBRAIM prospective observational trial
Magri, V;Palleschi, M;Cognetti, F
2021
Abstract
Background: Eribulin shows some activity in controlling brain metastasis in breast cancer. Methods: This observational, multicenter study evaluated brain disease control rates, survival and safety in patients with brain metastatic breast cancer treated with eribulin in clinical practice. Results: A total of 34 patients were enrolled (mean age 49 years, 91% with visceral metastases) and 29 were evaluable for brain disease. Fourteen achieved disease control and showed a longer time without progression: 10 months (95% CI: 2.3-17.7) versus 4 months (95% CI: 3.3-4.7) in the control group (p = 0.029). Patients with clinical benefits at 6 months had longer survival. Leukopenia and neutropenia were the most frequent grade 3-4 toxicities. Conclusion: Eribulin confirms its effectiveness in patients with brain metastatic breast cancer. Further studies on larger cohorts are needed to confirm the results.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabi_Eribulin-in-brain_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.05 MB
Formato
Adobe PDF
|
2.05 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
